|
|
2050 Rene-Levesque Blvd W., 6th Floor
Quebec, QC G1V 2K8 Canada
phone:(418) 527-6100
fax:(418) 527-0240
|
|
| Symbol |
CUR |
| Exchange |
TSX |
| Founded |
1994 |
| Employees |
50 |
|
|
| www.diagnocure.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Develops and Provides Diagnostic Tests for Cancer Detection and Management |
|
| Management |
| John C. Schafer, President and Chief Executive Officer; Jean-Fran?ois Bureau, CFA, Senior Vice President and Chief Financial Officer; Dr Yves Fradet, Senior Vice President and Chief Medical Officer; Paule De Blois, Vice President, Corporate Affairs; Richard Gauthier, Vice President, Business Development; Timothy J. Holzer, Vice President and Chief Scientific Officer; Phillip Wells, Vice President, Marketing and National Sales |
| |
|
|
|
|
|
|
|
| Keywords |
| diagnostics, urology, advamed, Colorectal Cancer, GCC, PrevistageTM GCC, Molecular diagnostic tests, Prostate cancer, PCA3 |
|
|
|
| Description |
|
DiagnoCure develops and commercializes tests and lab services facilitating cancer detection and diagnosis. The company specializes in molecular tests that detect irregular gene or protein activity patterns associated with cancer, thus increasing clinician and patient confidence in making critical treatment decisions. |
|
| Products / Services |
DiagnoCure first entered the bladder cancer market with Immunocyt(TM)/uCyt+(TM), a non-invasive test for superficial bladder cancer detection. Its latest product pipeline includes: the PCA3 prostate cancer test, the Previstage(TM) GCC colorectal cancer staging test, and the GCC colorectal cancer monitoring test. The company has developed prognostic markers for lung and prostate cancers, as well as the Shc line of prognostic tests for colorectal cancer, breast cancer, gastric cancer, and melanoma.
|
|
| Technology / Differentiation |
| Compared to traditional pathology methods, which can detect one cancer cell in 200 normal cells, molecular technologies can detect one cancer cell in up to 10 million normal cells. This represents a significant improvement in providing the vital information physicians need to make optimal decisions about their patients' treatments. PCA3 is a genetic marker specific for prostate cancer; the uPM3(TM) is a urine-based diagnostic test used to detect PCA3 RNA expression. The GCC receptor is found specifically on colorectal cells, forming the basis of a highly sensitive method (Previstage(TM) GCC) of colorectal cancer detection since it relies on messenger RNA-based amplification technology. Most recently, the Shc prognostic tests measure the level of activated tyrosine phosphorylated (PY) Shc protein and p66 Shc protein in tissue specimens. These proteins are involved in many well-documented cellular pathways associated with tumor aggressiveness in many cancers, serving as strong indicators for risk of disease recurrence and predictors of response to various courses of treatment. |
|
| Market / Customers |
Prostate cancer is the most frequent cancer and second leading cause of cancer death in men, representing an estimated market of 1.8 million tests per year in North America and Europe. Colorectal cancer is the second most fatal form of cancer, with an overall 5-year survival rate of 64%. 174,000 new diagnostics and 31,000 deaths are confirmed each year in North America. The initial market for Previstage GCC is approximately 97,000 Americans and Canadians who each year are staged I and II after their colorectal cancer surgery.
|
|
| Status |
| ImmunoCyt (TM) has FDA clearance for commercialization in the United States for the monitoring of bladder cancer. DiagnoCure launched its Previstage(TM) GCC Colorectal Cancer Staging Test in August 2008 and holds exclusive rights to the GCC marker. The company has a strategic alliance with Gen-Probe for the development and commercialization of a second-generation prostate cancer test using PCA3. PCA3-based tests are available through several American, European and Canadian laboratories. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
